RUBY Rubius Therapeutics Inc

H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Rubius Therapeutics (RUBY – Research Report) today and set a price target of $15.00. The company's shares closed last Friday at $3.19, close to its 52-week low of $3.00. According to TipRanks.com, Fein is ranked 0 out of 5 stars with an average return of -5.3% and a 37.8% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA - American, Amylyx Pharmaceuticals Inc, and Deciphera Pharmaceuticals. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Rubius Therapeutics with a $10.00 average price target.
https://www.tipranks.com/news/blurbs/rubius-therapeutics-ruby-gets-a-buy-rating-from-h-c-wainwright?utm_source=advfn.com&utm_medium=referral